Nearly 200 studies in: what cannabis research actually showed in the first half of 2026

Roundups counting the year’s cannabis research put the 2026 tally near 200 published studies, and the picture they paint is more nuanced than either side of the debate usually admits. On the upside, new work suggests CBD and THC may interfere with pathways involved in glioblastoma growth, and a clinical trial found low-dose THC-CBD extracts helped stabilize cognitive decline in dementia patients over six months.

There is encouraging safety data too: a randomized trial reported that low-dose, full-spectrum CBD was well tolerated in adults living with virally suppressed HIV, with no meaningful hit to liver or kidney function. These are the kinds of carefully scoped findings that move medical cannabis from anecdote toward evidence.

The counterweight is potency. Meta-analyses continue to show average THC levels have more than doubled over time while CBD has fallen, and the mental-health literature on high-potency products remains genuinely mixed. ‘Cannabis is medicine’ and ‘today’s flower is far stronger than the research base assumes’ are both true at once.

For anyone selling or reviewing product, the honest move is to hold both ideas. The science is getting better and more specific — which means the lazy, one-size-fits-all health claims are aging worse every quarter.